Remarkably, hepatocyte-specific knockdown of mARC1 in mice resulted in a similar effect on liver fibrosis as observed in the FLIGHT-FXR study with significantly decreased zone 2 fibrosis and reduced co-localization steatosis and inflammation with fibrosis revealing the translational potential of targeting mARC1 for the treatment of liver fibrosis. The gene discussed is NR1H4; the disease is Hepatic fibrosis.